Cardiff Oncology, INC

Cardiff Oncology announced positive Phase 2 data for onvansertib in first-line RAS-mutated mCRC, aligned with the FDA on a registrational trial set for Q1 2027, and secured $10 million in financing, but still requires additional funding.

Cardiff Oncology announced a $10 million registered direct offering of common stock and warrants to fund working capital and general corporate purposes.

Cardiff Oncology announced positive Phase 2 data for onvansertib in combination with chemotherapy and bevacizumab for first-line RAS-mutated metastatic colorectal cancer, paving the way for a pivotal Phase 3 trial.

Cardiff Oncology is contesting a purported termination of its 2017 license agreement with Nerviano Medical Sciences.

Cardiff Oncology has filed a lawsuit against Nerviano Medical Sciences (NMS) to dispute allegations of a material breach of their license agreement for onvansertib.

Cardiff Oncology announced first quarter 2026 financial results, highlighting a successful End-of-Phase 2 meeting with the FDA for its onvansertib Phase 3 trial and updated clinical data presentations.

Cardiff Oncology's Q2 2026 report highlights ongoing litigation with NMS, substantial doubt about its going concern status, and a registered direct offering to raise capital, alongside promising clinical trial updates for onvansertib.

Cardiff Oncology reports a reduced net loss in Q3 2025, driven by decreased R&D expenses, while its lead asset onvansertib continues to show promising clinical trial results in multiple cancer indications.

Cardiff Oncology's latest quarterly report reveals a significant increase in net loss and cash burn, while highlighting positive clinical data for its lead asset, onvansertib, across multiple cancer indications and securing a new patent.

Cardiff Oncology's Q1 2025 report reveals increased R&D spending and a net loss, but the company believes it has sufficient cash to fund operations into Q1 2027.

Cardiff Oncology's Q3 2024 report details financial results, clinical trial progress, and a focus on their lead drug candidate, onvansertib.

Cardiff Oncology's Q2 2024 report details financial results, clinical trial progress, and a focus on their lead drug candidate, onvansertib.

Cardiff Oncology's latest 10-K reveals promising clinical trial data for onvansertib in mCRC and mTNBC, but highlights significant financial challenges and a going concern warning.

Cardiff Oncology, a clinical-stage biotechnology company, details its financial performance for 2024 and outlines key developments in its oncology drug development programs.

Cardiff Oncology's 10-K filing details the company's financial status, clinical trial progress, and future plans, highlighting its focus on onvansertib development.

Gary W Pace, a Director of Cardiff Oncology, Inc., purchased 1,374,570 shares of common stock on July 14, 2026 for $1.46 per share.

Mani Mohindru, Chief Executive Officer and a Director of Cardiff Oncology, Inc., purchased 68,728 shares of common stock on July 14, 2026 for $1.46 per share.

Director James O. Armitage was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a standard equity compensation arrangement.

Director Lale White was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a standard equity compensation arrangement.

Director Renee P. Tannenbaum was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a routine equity compensation.

Director Rodney S. Markin was granted 40,565 stock options in Cardiff Oncology, Inc. as part of a standard equity compensation update.

Cardiff Oncology, Inc. has issued its 2026 proxy statement detailing proposals for director elections, auditor ratification, and an increase in equity incentive plan shares.

Cardiff Oncology's upcoming annual meeting will address director elections, auditor ratification, an equity incentive plan amendment, and executive compensation.

Cardiff Oncology is holding its annual meeting of stockholders on June 26, 2025, to vote on key proposals including the election of directors, ratification of the accounting firm, an increase to the equity incentive plan, and executive compensation.

Cardiff Oncology is seeking stockholder approval for replacement stock option grants after rescinding previous grants made in reliance on a 2022 amendment to the 2021 Equity Incentive Plan.

Cardiff Oncology amended its by-laws to clarify voting standards and address a stockholder lawsuit alleging improper voting procedures.

Cardiff Oncology's upcoming annual meeting on June 20, 2024, will address the election of directors, ratification of auditors, an amendment to the equity incentive plan, and executive compensation.

The Vanguard Group, Inc. has amended its Schedule 13G filing for Cardiff Oncology Inc, reporting 0% beneficial ownership due to an internal corporate realignment.

Commodore Capital LP and Commodore Capital Master LP report zero beneficial ownership in Cardiff Oncology, Inc., indicating a full divestment of their previous stake.

The Vanguard Group has reported a 5.6% beneficial ownership stake in Cardiff Oncology Inc., holding 3,728,334 shares of common stock as of June 30, 2025.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Cardiff Oncology, Inc. as of March 31, 2025.

Pfizer Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 3.6% of Cardiff Oncology, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.3% passive beneficial ownership stake in Cardiff Oncology, Inc. as of December 31, 2024.